Evidence map›Paper›PMID 36508113›Full record

ArticleCEN case reports2023

IgA nephropathy diagnosed as a result of acute exacerbation due to G-CSF administration.

Keita Hattori, Ryo Shimizu, Shoichiro Tanaka, Takashi Terashima, Ryosuke Ishikawa, Michiko Yamazaki, Tomoharu Watanabe, Hirofumi Tamai

Open access · greenAbstract readCase Reports
In one paragraph

Article in CEN case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Keita HattoriDepartment of Nephrology, Toyohashi Municipal Hospital, 50, Hachikennishi, Aotakecho, Toyohasi, Aichi, 441-8570, Japan. hattori.keita@gmail.com.ORCID 0000-0002-1070-8649
Ryo ShimizuDepartment of Nephrology, Anjo Kosei Hospital, 28, Higashihirokute, Anjocho, Anjo, Aichi, 446-8602, Japan.
Shoichiro TanakaDepartment of Nephrology, Anjo Kosei Hospital, 28, Higashihirokute, Anjocho, Anjo, Aichi, 446-8602, Japan.
Takashi TerashimaDepartment of Nephrology, Anjo Kosei Hospital, 28, Higashihirokute, Anjocho, Anjo, Aichi, 446-8602, Japan.
Ryosuke IshikawaDepartment of Nephrology, Toyohashi Municipal Hospital, 50, Hachikennishi, Aotakecho, Toyohasi, Aichi, 441-8570, Japan.
Michiko YamazakiDepartment of Nephrology, Toyohashi Municipal Hospital, 50, Hachikennishi, Aotakecho, Toyohasi, Aichi, 441-8570, Japan.
Tomoharu WatanabeDepartment of Nephrology, Toyohashi Municipal Hospital, 50, Hachikennishi, Aotakecho, Toyohasi, Aichi, 441-8570, Japan.
Hirofumi TamaiDepartment of Nephrology, Anjo Kosei Hospital, 28, Higashihirokute, Anjocho, Anjo, Aichi, 446-8602, Japan.
Anjo Kosei Hospital · JPToyohashi Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Granulocyte colony-stimulating factor (G-CSF) is commonly used to stimulate bone marrow production. G-CSF is usually safe but sometimes causes serious adverse effects and, in rare cases, exacerbates glomerulonephritis. We report a case of immunoglobulin A (IgA) nephropathy that was aggravated by G-CSF. A 56-year-old Japanese man with no relevant medical history was admitted to our hospital as a donor of peripheral blood stem cells (PBSCs) for transplantation. To mobilize PBSCs, he received subcutaneous G-CSF (lenograstim), 500 μg for 4 days. Three days after the first dose of lenograstim, gross hematuria appeared, and after administration on the fourth day, renal dysfunction and nephrotic-range proteinuria were observed. Renal biopsy and light microscopic study revealed mild mesangial proliferation with expansion in association with the presence of cellular segmental crescents. Immunofluorescence study revealed diffuse, granular staining in the mesangium for IgA, complement component 3 (C3), and lambda light chains. We diagnosed highly active IgA nephropathy and initiated treatment with prednisolone and azathioprine. Three months later, renal function returned to normal. Screening for hidden chronic glomerulonephritis should be performed when G-CSF is administered, as in PBSC donors. Immunosuppressant therapy, such as prednisolone or azathioprine, is considered for exacerbations of highly active glomerulonephritis.

Indexed as

GlomerulonephritisGlomerulonephritis, IGAAzathioprineGranulocyte Colony-Stimulating FactorHumansImmunoglobulin ALenograstimMaleMiddle AgedPrednisoloneAzathioprineGranulocyte Colony-Stimulating FactorImmunoglobulin ALenograstimPrednisoloneGranulocyte colonyIgA nephropathyPeripheral blood stem cell transplantationStimulating factor

Identifiers

PMID36508113
PMCPMC10393928
OpenAlexW4311200173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.